Owlstone Medical delivers breath biopsy test data
Preliminary data has shown excellent safety, while also demonstrating proof of mechanism
Read Moreby John Pinching | Jun 14, 2023 | News | 0
Preliminary data has shown excellent safety, while also demonstrating proof of mechanism
Read Moreby John Pinching | Mar 15, 2023 | News | 0
Duo team up for the development of antigen-targeted probes for early cancer detection
Read Moreby Anna Smith | Nov 8, 2019 | News | 0
If successful, Thermo’s mass analyser will become a standard part of Owlstone Medical’s biomarker discovery process.
Read Moreby Anna Smith | May 20, 2019 | News | 0
Currently, early diagnosis of PH is very difficult and a delay of years between the onset of symptoms and diagnosis and treatment is unfortunately common.
Read Moreby Selina McKee | Nov 27, 2017 | News | 0
In a major boon for UK diagnostics group Owlstone Medical, GlaxoSmithKline is incorporating the firm’s Breath Biopsy platform into the clinical development programme for its novel, experimental respiratory drug danirixin.
Read Moreby Selina McKee | Jul 10, 2017 | News | 0
UK diagnostics group Owlstone Medical and Cancer Research UK have kicked off a study aiming to identify breath biomarkers to improve the early detection and diagnosis of multiple cancer types.
Read Moreby Selina McKee | Feb 7, 2017 | News | 0
UK diagnostics group Owlstone Medical has kicked off a 1,400 patient clinical trial assessing the potential of its FAIMS (Field Asymmetric Ion Mobility Spectrometer) technology in the early detection of colorectal cancer, which it claims to be the world’s largest breath-based study into the disease.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
